Registration of Manufacturers, Distributors and Dispensers of Controlled Substances
DEA registration requirements for every person manufacturing, distributing, dispensing, importing or exporting controlled substances, including the physical-security and employee-screening obligations that attach to registration.
What this does not cover
stated in the document's own scope- Governs registration and security for controlled substances, not product quality or manufacturing GMP, which fall under 21 CFR 210/211.
- Sits outside the ICH / PIC/S GMP harmonisation architecture; its remit is diversion control under the Controlled Substances Act.
- Covers registration and physical security; the associated records and reports are the subject of 21 CFR Part 1304.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
21 CFR Part 1301 sets the DEA registration requirements for every person who manufactures, distributes, dispenses, imports, or exports controlled substances. It establishes who must register, how registration is applied for, renewed, modified, and terminated, and the separate registration required for each principal place of business and each independent activity. It also carries the obligations that attach to being registered: the physical-security controls appropriate to the schedule and quantity of substances handled, and the screening of employees who have access to controlled substances. Registration is the gateway that makes lawful handling of controlled substances possible.
Scope & applicability
Any site handling scheduled substances — including R&D quantities and reference standards. Registration is per site and per business activity, not per company.
Legal basis & how it acquires force
Part 1301 is a binding federal regulation in Title 21 of the Code of Federal Regulations, issued by the Drug Enforcement Administration under the Controlled Substances Act. Its requirements are legal obligations, not guidance. Importantly, the DEA operates outside the GMP and international harmonisation architecture: it is not part of ICH or PIC/S, and its remit is the prevention of diversion of controlled substances, not product quality. A firm may hold DEA registration and be subject to Part 1301 entirely separately from its FDA GMP obligations.
Document structure
| Part | Covers |
|---|---|
| Registration requirement | Persons required to register and the separate registration for each activity and location |
| Application, renewal, and modification | How to apply for, renew, modify, or terminate a registration |
| Coincident activities and exemptions | Activities authorised by a registration and specific exemptions |
| Security requirements | Physical-security controls for storage, scaled to schedule and quantity, and controls for practitioners and non-practitioners |
| Employee screening | Screening of personnel with access to controlled substances and reporting of employee drug diversion |
| Denial, suspension, and revocation | Grounds and procedures for denying, suspending, or revoking a registration |
Key requirements
- Current DEA registration for each site and each business activity
- Physical security controls appropriate to the schedules handled
- Employee screening programme and diversion-reporting procedures
- Notification to DEA on relevant changes
Implementation tips
- Include DEA scope in change control — a new schedule, a higher quantity or a new activity can each trigger a registration or security change
- Run security assessments against the regulation rather than against habit; requirements step up with schedule and volume
- DEA rulemaking appears in the Federal Register, so it is already reachable through a Federal Register feed
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Part 1301 works together with the DEA recordkeeping and reporting rules in 21 CFR Part 1304, the order-form rules in Part 1305, and the schedules in Part 1308 — collectively the DEA controlled-substances framework under the Controlled Substances Act. This framework is deliberately distinct from FDA GMP: a controlled-substance manufacturer must satisfy both, but DEA registration and security requirements address diversion control, while GMP addresses product quality.
21 CFR Part 1301: frequently asked questions
Quick answers to common questions about 21 CFR Part 1301.
Who must register under 21 CFR Part 1301?
Every person who manufactures, distributes, dispenses, imports, or exports controlled substances, with a separate registration generally required for each principal place of business and each independent activity.
Is DEA Part 1301 part of GMP?
No. The DEA operates outside the GMP and ICH/PIC-S harmonisation architecture. Part 1301 addresses registration and physical security to prevent diversion of controlled substances — not product quality, which is the domain of FDA GMP.
What obligations attach to DEA registration?
Beyond registering itself, a registrant must meet the physical-security controls appropriate to the schedule and quantity of controlled substances it handles and screen employees who have access to them.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.